EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - Generic Drug Details

What are the generic drug sources for efavirenz; lamivudine; tenofovir disoproxil fumarate and what is the scope of patent protection?

Efavirenz; lamivudine; tenofovir disoproxil fumarate is the generic ingredient in three branded drugs marketed by Aurobindo Pharma Ltd, Laurus, Macleods Pharms Ltd, Mylan Labs Ltd, and Mylan, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.

Two suppliers are listed for this compound.

Summary for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

US Patents:	0
Tradenames:	3
Applicants:	5
NDAs:	6
Finished Product Suppliers / Packagers:	2
Clinical Trials:	28
DailyMed Link:	EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE at DailyMed

Recent Clinical Trials for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida	N/A
Professor Francois Venter	Phase 3
Yu-Jay Corp.	Phase 3

See all EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE clinical trials

Pharmacology for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inhibitors Cytochrome P450 2C9 Inhibitors Cytochrome P450 3A Inducers Cytochrome P450 3A4 Inhibitors Non-Nucleoside Reverse Transcriptase Inhibitors Nucleoside Reverse Transcriptase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J05AG	Non-nucleoside reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	022343-001	Aug 15, 2018		DISCN	Yes	No
Macleods Pharms Ltd	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE	efavirenz; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	210649-001	Mar 15, 2019		DISCN	No	No
Mylan	SYMFI LO	efavirenz; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	208255-001	Feb 5, 2018		DISCN	Yes	No

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate?

The combined sales of efavirenz, lamivudine, and tenofovir disoproxil fumarate address a large segment of HIV treatment. The drugs are integral to first-line antiretroviral therapy (ART), contributing to the majority of global HIV regimens. The market's foundational drivers include global HIV prevalence, treatment guidelines, patent statuses, and the emergence of new therapies.

• Global HIV Burden: As of 2022, approximately 38 million people globally live with HIV, with 1.7 million new infections reported in 2021. Sub-Saharan Africa accounts for 70% of cases, emphasizing regional differences in market demand.
• Treatment Guidelines: The WHO recommends TDF (tenofovir disoproxil fumarate)-based regimens as first-line treatments for adults and adolescents, supported by robust evidence of efficacy and tolerability.
• Patent and Patent Expirations: Patents for efavirenz (Branded: Sustiva), lamivudine (Epivir), and tenofovir disoproxil fumarate (Viread) have expired or are nearing expiration in many markets, leading to increased generic competition.
• Generic Market Expansion: Generics dominate the global market, with large suppliers in India and China providing cost-effective options. This shift increases access but pressures branded sales.

How Have Patent Expirations Influenced Market Trends?

Patents for these drugs expired in key markets:

• Efavirenz: Patent expired in the US in 2018. Generic versions entered at significantly lower prices, reducing branded sales.
• Lamivudine: Patent expired in the US in 2005. Generics have since been dominant.
• Tenofovir Disoproxil Fumarate: Patent expired in the US in 2020, leading to increased competition and price reductions.

The decline in branded sales in high-income markets contrasts with sustained demand in lower-income regions where generics are dominant. For instance, WHO estimates that over 90% of HIV treatment in Africa uses generic TDF-based regimens.

What Are the Factors Impacting Financial Trajectory?

The revenue from these drugs has shifted from branded to generic markets, impacting profitability and market size:

Parameter	Pre-Patent Expiry (Pre-2018)	Post-Patent Expiry (Post-2018)	Impact
Branded Sales (USD)	~$2 billion globally (peak)	Declines by 70% after patent expirations	Loss of revenue for originators, increased generic uptake
Generic Market Share	<10%	>80% in many developing markets	Price reductions, wider access
Price per Treatment Course	~$1,000–$2,000	<$100 in generics	Market expansion driven by affordability

Despite falling revenues in high-income markets, the overall market remains sizable due to increasing global treatment coverage, especially as WHO recommends broad-scale ART.

What Are the R&D and Regulatory Trends?

Developers are investing in fixed-dose combinations (FDCs) and long-acting formulations. Companies aim to reduce pill burden and improve adherence:

• Long-acting injectables: Cabotegravir and rilpivirine have entered markets, offering alternatives to daily oral regimens.
• Next-generation drugs: Tenofovir alafenamide (TAF), a safer and more potent TDF alternative, has gained prominence, potentially substituting TDF in legacy regimens.
• Regulatory pathways: Rapid approvals for generics have accelerated market entry, especially in low-income nations, impacting the revenues of originator firms.

How Is Market Competition Affecting Future Growth?

The proliferation of generics has compressed margins. Leading originator companies face revenue declines:

• Gilead Sciences: Historically dominant with Viread and Atripla, Gilead's revenues decreased as generics expanded.
• Abrupt shifts: In markets like India and South Africa, local manufacturers supply affordable generics, enabling widespread use.
• Emerging innovations: Companies developing long-acting formulations and novel delivery systems seek to regain market share. These include biotech companies like ViiV Healthcare and Janssen.

The global value of the antiretroviral drugs segment was valued at approximately USD 9.4 billion in 2020 and is projected to expand modestly at a compound annual growth rate (CAGR) of around 3% through 2025, driven principally by volume growth in emerging markets.

What Is the Financial Outlook for These Drugs?

The revenue trends for efavirenz, lamivudine, and tenofovir disoproxil fumarate reflect a transition:

• Branded sales: Declining due to patent expiries, with some brands phased out or replaced.
• Generic sales: Dominating the market, with continued growth in volume, but lower profit margins.
• Market expansion: Driven by increased HIV treatment coverage, especially in low-income regions.

Major pharmaceutical companies' revenues from legacy HIV drugs are plateauing or declining. Conversely, investments in new formulations and combination therapies represent potential revenue sources.

Key Takeaways

• The patent expiration of efavirenz, lamivudine, and tenofovir disoproxil fumarate has shifted the market from branded to generic dominance, reducing overall revenues in high-income markets.
• Global HIV treatment demand sustains the market, especially in low-income regions where generics have expanded access.
• R&D investments focus on long-acting formulations and safer alternatives like tenofovir alafenamide, potentially transforming future revenue streams.
• The market growth rate has slowed, averaging 3-4% CAGR through 2025, with regional variations.
• Competition from local generic manufacturers and newer therapies pressures traditional market players.

FAQs

1. How do patent expiries influence drug prices?
Patent expiries enable generic manufacturers to enter the market, significantly reducing drug prices and increasing access, especially in low-income regions.

2. Will branded drug sales rebound with new formulations?
Long-acting injectables and novel delivery systems have shown promise but are unlikely to reverse declining sales of older formulations in mature markets.

3. Which regions offer the highest growth potential?
Sub-Saharan Africa and parts of Asia offer the highest growth potential due to expanding HIV treatment access and reliance on generics.

4. How does the shift to generics impact pharmaceutical innovation?
Reduced revenues from legacy drugs incentivize investment in next-generation therapies and formulations rather than traditional small-molecule drugs.

5. What is the outlook for tenofovir alafenamide (TAF)?
TAF is gaining approval as a safer, more potent alternative to TDF, and is expected to replace TDF in many fixed-dose regimens, opening new revenue opportunities.

---

Sources

1. UNAIDS. Global HIV & AIDS statistics — 2022 fact sheet.
2. WHO. Consolidated guidelines on HIV prevention, diagnosis, treatment, and care for key populations. 2021.
3. IQVIA. Global HIV Medicines Market Report, 2022.
4. Gilead Sciences Annual Report 2022.
5. ViiV Healthcare. Long-acting injectable HIV treatment, 2022.